MedPath

Dose Ranging Study of Dronedarone for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation

Phase 2
Completed
Conditions
Atrial Fibrillation
Interventions
Registration Number
NCT01213368
Lead Sponsor
Sanofi
Brief Summary

Primary Objective:

- To assess the efficacy of dronedarone versus placebo for the control of ventricular rate in patients with permanent Atrial Fibrillation (AF).

Secondary Objective:

* To assess the safety and tolerability of dronedarone after repeated oral doses of 300 mg, 400 mg, or 600 mg twice daily in the selected population.

* To document SR33589 and SR35021 trough plasma levels at steady state.

Detailed Description

The study period per patient is approximatively 1 month broken down as follows:

* Screening period up to 7 days,

* Treatment period of 14 days,

* Follow-up period of 10 days.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
181
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
dronedarone 300 mgDRONEDARONE (SR33589)Dronedarone, 100mg + 200mg tablets twice daily, administered with food.
dronedarone 400 mgDRONEDARONE (SR33589)Dronedarone, 400mg tablets twice daily, administered with food.
dronedarone 600 mgDRONEDARONE (SR33589)Dronedarone, 400mg + 200mg tablets twice daily, administered with food.
placeboplaceboMatching placebo tablets twice daily, administered with food.
Primary Outcome Measures
NameTimeMethod
Change from baseline in mean ventricular rate measured by 24-hour Holter Electrocardiogram (ECG)Day 14
Secondary Outcome Measures
NameTimeMethod
Number of patients with adverse eventsup to 10 days after last drug intake
Plasma trough concentrations for SR35021Day 14
Plasma trough concentrations for SR33589Day 14

Trial Locations

Locations (25)

Investigational Site Number 392008

🇯🇵

Kawasaki-Shi, Japan

Investigational Site Number 392019

🇯🇵

Nagasaki-Shi, Japan

Investigational Site Number 392010

🇯🇵

Osaka-Shi, Japan

Investigational Site Number 392020

🇯🇵

Suwa-Shi, Japan

Investigational Site Number 392023

🇯🇵

Miyazaki-Shi, Japan

Investigational Site Number 392012

🇯🇵

Kobe-Shi, Japan

Investigational Site Number 392013

🇯🇵

Kobe-Shi, Japan

Investigational Site Number 392022

🇯🇵

Hiroshima-Shi, Japan

Investigational Site Number 392005

🇯🇵

Kasama-Shi, Japan

Investigational Site Number 392007

🇯🇵

Kisarazu-Shi, Japan

Investigational Site Number 392018

🇯🇵

Kagoshima-Shi, Japan

Investigational Site Number 392014

🇯🇵

Kawanishi-Shi, Japan

Investigational Site Number 392024

🇯🇵

Toshima-Ku, Japan

Investigational Site Number 392003

🇯🇵

Koriyama-Shi, Japan

Investigational Site Number 392017

🇯🇵

Kurume-Shi, Japan

Investigational Site Number 392009

🇯🇵

Nagano-Shi, Japan

Investigational Site Number 392011

🇯🇵

Yao-Shi, Japan

Investigational Site Number 392025

🇯🇵

Sapporo-Shi, Japan

Investigational Site Number 392004

🇯🇵

Shirakawa-Shi, Japan

Investigational Site Number 392015

🇯🇵

Ube-Shi, Japan

Investigational Site Number 392021

🇯🇵

Sapporo-Shi, Japan

Investigational Site Number 392016

🇯🇵

Shunan-Shi, Japan

Investigational Site Number 392006

🇯🇵

Takasaki-Shi, Japan

Investigational Site Number 392002

🇯🇵

Sendai-Shi, Japan

Investigational Site Number 392001

🇯🇵

Tomakomai-Shi, Japan

© Copyright 2025. All Rights Reserved by MedPath